var data={"title":"Metyrapone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Metyrapone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6574?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=metyrapone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Metyrapone: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12806507\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Metopirone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196015\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Diagnostic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195998\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ACTH function testing</b>: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Single-dose/overnight test: 30 mg/kg (maximum: 3 g) at midnight</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Multiple-dose test: 750 mg every 4 hours for 6 doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cushing syndrome (off-label use):</b> Oral: Initial: 250 mg 4 times a day; dosage range: 500 mg to 6,000 mg daily in divided doses every 6 to 8 hours; maximum daily dose: 6,000 mg (Biller 2008; ES [Neiman 2015])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196007\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=metyrapone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Metyrapone: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>ACTH function testing</b>: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Single-dose/overnight test:</i> 30 mg/kg (maximum: 3 g) at midnight</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Multiple-dose test:</i> 15 mg/kg (minimum: 250 mg; maximum: 750 mg) every 4 hours for 6 doses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195999\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20324079\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20324080\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195988\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metopirone: 250 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195977\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11345045\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Metopirone&reg; is available from HRA Pharma via special allocation only. Contact the manufacturer for additional information at 855-674-7663.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11345073\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Single-dose test: Administer to patients with adequate waking cortisol concentrations (&gt;200 nmol/L) (Wallace 2009). Administer dose at midnight with yogurt or milk. Blood samples are taken the following morning (7:30-8:00 am). Administer prophylactic dose of cortisone acetate 50 mg after samples are obtained.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multiple-dose test: Administer with milk or snack 3 days following ACTH test. Urine is collected for 24 hours following the last day of administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195989\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>ACTH function testing</b>: Diagnostic test for hypothalamic-pituitary ACTH function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25730635\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cushing syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196020\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">MetyraPONE may be confused with metyroSINE</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195982\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache, sedation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Allergic skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal discomfort, abdominal pain, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Bone marrow depression, decreased white blood cell count</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195991\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to metyrapone or any component of the formulation; patient with adrenal cortical insufficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195980\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Reduced adrenal secretory capacity: Acute adrenal insufficiency may be induced in patients with reduced adrenal secretory capacity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thyroid disease: Response to test may be subnormal in patients with hypo- or hyperthyroidism. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196012\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2A6 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195983\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10156&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: MetyraPONE may increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of MetyraPONE. The oral metyrapone test would thus be unreliable unless the metapyrone dosage was substantially increased (e.g., 750 mg every 2 hours).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of MetyraPONE. The oral metyrapone test would thus be unreliable unless the metapyrone dosage was substantially increased (e.g., 750 mg every 2 hours).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: MetyraPONE may increase serum concentrations of the active metabolite(s) of Propacetamol. Specifically, metyrapone may increase acetaminophen exposure. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism toward the oxidative route that produces a hepatotoxic metabolite. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195985\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195992\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adequate animal reproduction studies have not been conducted. When used as a diagnostic test during the second and third trimesters of pregnancy, the fetal pituitary responded to the enzymatic block. A subnormal response to testing may occur in pregnant women.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Untreated Cushing syndrome during pregnancy may cause adverse events in the mother and fetus (Bronstein 2015; Kamoun 2014). Use of metyrapone for the treatment of Cushing syndrome has been noted in case reports (Bronstein 2015; Nieman 2015). When medical therapy is needed, treatment is generally started in the second or third trimesters (Bronstein 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11345047\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Metyrapone is excreted in breast milk. The excretion of metyrapone and its active metabolite metyrapol into breast milk are described in a case report. The mother had been taking metyrapone 250 mg 4 times daily for 9 weeks and was 1 week postpartum when milk samples were obtained. Multiple milk samples taken ~1 to 5 hours after the dose contained average concentrations of metyrapone 11.2 mcg/L and metyrapol 48.5 mcg/L over the dosing interval. The relative infant dose (metyrapone and metyrapol) was calculated to be 0.1% of the weight adjusted maternal dose (Hotham 2009). The manufacturer recommends that caution be exercised when administering metyrapone to breast-feeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11345070\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Take with milk or snack.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11345076\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Single-dose test: 11-deoxycortisol concentrations &lt;200 nmol/L are diagnostic for adrenal insufficiency (Wallace 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multiple dose test: Normal response following the test is a two- to fourfold urinary increase in 17-OHCS excretion or doubling of 17-KGS excretion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11345075\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Normal 24-hour urinary excretion of 17-OHCS: 3 to 12 mg (increases to 15 to 45 mg following ACTH infusion of 50 units over 8 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11345064\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Metyrapone inhibits the production of cortisol; blockade can be measured by the urinary increase of the metabolites of cortisol precursors in the urine (17-hyroxycorticosteroids [17-OHCS] and 17-ketogenic steroids [17-KGS]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11345066\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: Peak steroid excretion: Within 24 hours of administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Well absorbed; rapid </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Reduced to metyrapol (active metabolite); parent drug and metabolite also undergo glucuronide conjugation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Metyrapone: 1.9 &plusmn; 0.7 hours; Metyrapol (active metabolite): Takes twice as long as metyrapone to be eliminated </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine; ~5% as metyrapone (primarily as glucuronide conjugate) and ~38% as metyrapol (primarily as glucuronide conjugate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323397\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Metopirone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (18): $381.47</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038679\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Metopiron (CH, GB, NL, NO, SE);</li>\n      <li>Metopirone (AU, CZ, FR, GR, HK, IE, IL, MT, NZ, PL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Biller BM, Grossman AB, Stewart PM, et al, &quot;Treatment of Adrenocorticotropin-Dependent Cushing's Syndrome: A Consensus Statement,&quot; <i>J Clin Endocrinol Metab</i>, 2008, 93(7):2454-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metyrapone-drug-information/abstract-text/184134274/pubmed\" target=\"_blank\" id=\"184134274\">184134274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bronstein MD, Machado MC, Fragoso MC. Management of endocrine disease: Management of pregnant patients with Cushing's syndrome. <i>Eur J Endocrinol</i>. 2015;173(2):R85-R91. doi: 10.1530/EJE-14-1130.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metyrapone-drug-information/abstract-text/25872515/pubmed\" target=\"_blank\" id=\"25872515\">25872515</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26353009\"></a>Daniel E, Aylwin S, Mustafa O, et al. Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. <i>J Clin Endocrinol Metab</i>. 2015;100(11):4146-4154. doi: 10.1210/jc.2015-2616.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metyrapone-drug-information/abstract-text/26353009/pubmed\" target=\"_blank\" id=\"26353009\">26353009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hotham NJ, Ilett KF, Hackett LP, et al, &quot;Transfer of Metyrapone and its Metabolite, Rac-Metyrapol, Into Breast Milk,&quot; <i>J Hum Lact</i>, 2009, 25(4):451-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metyrapone-drug-information/abstract-text/19759353/pubmed\" target=\"_blank\" id=\"19759353\">19759353</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kamoun M, Mnif MF, Charfi N, Kacem FH, Naceur BB, Mnif F, Dammak M, et al. Adrenal diseases during pregnancy: pathophysiology, diagnosis andmanagement strategies. <i>Am J Med Sci</i>. 2014;347(1):64-73. doi:10.1097/MAJ.0b013e31828aaeee.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metyrapone-drug-information/abstract-text/23514671/pubmed\" target=\"_blank\" id=\"23514671\">23514671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metopirone (metyrapone) [prescribing information]. Farmingdale, NJ: Direct Success, Inc.; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nieman LK, Biller BM, Findling JW, et al; Endocrine Society. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(8):2807-2831. doi: 10.1210/jc.2015-1818.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metyrapone-drug-information/abstract-text/26222757/pubmed\" target=\"_blank\" id=\"26222757\">26222757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallace I, Cunningham S, and Lindsay J. &quot;The Diagnosis and Investigation of Adrenal Insufficiency in Adults,&quot; <i>Ann Clin Biochem</i>,2009, 46(Pt 5):351-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metyrapone-drug-information/abstract-text/19675057/pubmed\" target=\"_blank\" id=\"19675057\">19675057</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10156 Version 94.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F12806507\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F196015\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F195998\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F196007\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F195999\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20324079\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20324080\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F195988\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F195977\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11345045\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F11345073\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F195989\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25730635\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F196020\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F195982\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F195991\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F195980\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F196012\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F195983\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F195985\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F195992\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F11345047\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F11345070\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F11345076\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F11345075\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F11345064\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F11345066\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323397\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038679\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10156|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=metyrapone-pediatric-drug-information\" class=\"drug drug_pediatric\">Metyrapone: Pediatric drug information</a></li></ul></div></div>","javascript":null}